351 related articles for article (PubMed ID: 36525677)
1. Semaglutide 2.4-mg injection as a novel approach for chronic weight management.
Kyrillos J
Am J Manag Care; 2022 Dec; 28(15 Suppl):S297-S306. PubMed ID: 36525677
[TBL] [Abstract][Full Text] [Related]
2. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Ard J; Fitch A; Fruh S; Herman L
Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
[TBL] [Abstract][Full Text] [Related]
3. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
Amaro A; Sugimoto D; Wharton S
Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
[TBL] [Abstract][Full Text] [Related]
5. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
6. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
Singh G; Krauthamer M; Bjalme-Evans M
J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide for Weight Loss: Was It Worth the Weight?
Novograd J; Mullally J; Frishman WH
Cardiol Rev; 2022 Nov-Dec 01; 30(6):324-329. PubMed ID: 36201244
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide as a promising antiobesity drug.
Christou GA; Katsiki N; Blundell J; Fruhbeck G; Kiortsis DN
Obes Rev; 2019 Jun; 20(6):805-815. PubMed ID: 30768766
[TBL] [Abstract][Full Text] [Related]
10. Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
Amaro A; Skolnik NS; Sugimoto D
Postgrad Med; 2022 Jan; 134(sup1):18-27. PubMed ID: 36691308
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Moiz A; Levett JY; Filion KB; Peri K; Reynier P; Eisenberg MJ
Am J Cardiol; 2024 Jul; 222():121-130. PubMed ID: 38679221
[TBL] [Abstract][Full Text] [Related]
12. Clinical review of subcutaneous semaglutide for obesity.
Phillips A; Clements JN
J Clin Pharm Ther; 2022 Feb; 47(2):184-193. PubMed ID: 34964141
[TBL] [Abstract][Full Text] [Related]
13. The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials.
Alabduljabbar K; Al-Najim W; le Roux CW
Nutrients; 2022 May; 14(11):. PubMed ID: 35684020
[TBL] [Abstract][Full Text] [Related]
14. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
15. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
[TBL] [Abstract][Full Text] [Related]
16. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
Wright EE; Aroda VR
Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
[TBL] [Abstract][Full Text] [Related]
17. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
Kim HS; Jung CH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096
[TBL] [Abstract][Full Text] [Related]
18. [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
Scheen AJ
Rev Med Liege; 2019 Sep; 74(9):488-494. PubMed ID: 31486321
[TBL] [Abstract][Full Text] [Related]
19. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
20. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
Isaacs D; Prasad-Reddy L; Srivastava SB
Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]